Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Controlled release of 5-aminosalicylic acid (5-ASA) from new biodegradable polyurethanes.

Kenawy el-R, Al-Deyab SS, El-Newehy MH.

Molecules. 2010 Mar 30;15(4):2257-68. doi: 10.3390/molecules15042257.

2.

Novel pH-sensitive hydrogels for colon-specific drug delivery.

Mahkam M.

Drug Deliv. 2010 Apr;17(3):158-63. doi: 10.3109/10717541003604908.

PMID:
20141506
3.

Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid.

Wiwattanapatapee R, Lomlim L, Saramunee K.

J Control Release. 2003 Feb 14;88(1):1-9.

PMID:
12586498
4.

Biodegradable pH/temperature-sensitive oligo(β-amino ester urethane) hydrogels for controlled release of doxorubicin.

Huynh CT, Nguyen MK, Lee DS.

Acta Biomater. 2011 Aug;7(8):3123-30. doi: 10.1016/j.actbio.2011.05.004. Epub 2011 May 10.

PMID:
21601018
5.
6.
7.

Block poly(ester-urethane)s based on poly(3-hydroxybutyrate-co-4-hydroxybutyrate) and poly(3-hydroxyhexanoate-co-3-hydroxyoctanoate).

Chen Z, Cheng S, Xu K.

Biomaterials. 2009 Apr;30(12):2219-30. doi: 10.1016/j.biomaterials.2008.12.078. Epub 2009 Jan 23.

PMID:
19167751
8.

Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system.

Tenjarla S, Romasanta V, Zeijdner E, Villa R, Moro L.

Adv Ther. 2007 Jul-Aug;24(4):826-40.

PMID:
17901032
9.

5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.

Christensen LA, Jacobsen BA.

Neth J Med. 1989 Jun;35 Suppl 1:S3-10.

PMID:
2702310
10.

Bioavailability of controlled release mesalazine (5-ASA) preparations.

Rasmussen SN.

J Gastroenterol. 1995 Nov;30 Suppl 8:112-4.

PMID:
8563869
11.

[DDS preparations of drugs for inflammatory bowel disease].

Takada K.

Nihon Rinsho. 1999 Nov;57(11):2508-15. Review. Japanese.

PMID:
10572421
12.

A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.

Schellekens RC, Stuurman FE, van der Weert FH, Kosterink JG, Frijlink HW.

Eur J Pharm Sci. 2007 Jan;30(1):15-20. Epub 2006 Oct 4.

PMID:
17085024
13.

A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).

Thorpe MP, Ehrenpreis ED, Putt KS, Hannon B.

Aliment Pharmacol Ther. 2009 Jun 1;29(11):1193-201. doi: 10.1111/j.1365-2036.2009.03968.x. Epub 2009 Feb 15.

14.

Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.

Brzezinski A, Rankin GB, Seidner DL, Lashner BA.

Cleve Clin J Med. 1995 Sep-Oct;62(5):317-23. Review.

PMID:
7586488
15.

New pH-sensitive glycopolymers for colon-specific drug delivery.

Mahkam M.

Drug Deliv. 2007 Mar;14(3):147-53.

PMID:
17454034
16.

Design, synthesis and in vitro evaluation of vinyl ether type polymeric prodrugs of ibuprofen, ketoprofen and naproxen.

Babazadeh M.

Int J Pharm. 2008 May 22;356(1-2):167-73. doi: 10.1016/j.ijpharm.2008.01.003. Epub 2008 Jan 12.

PMID:
18289807
17.

A new degradable hydroxamate linkage for pH-controlled drug delivery.

Kenawy el-R, el-Newehy M, Abdel-Hay F, Ottenbrite RM.

Biomacromolecules. 2007 Jan;8(1):196-201.

PMID:
17206807
18.

Synthesis, degradation, and cytotoxicity of multiblock poly(epsilon-caprolactone urethane)s containing gemini quaternary ammonium cationic groups.

Ding M, Li J, Fu X, Zhou J, Tan H, Gu Q, Fu Q.

Biomacromolecules. 2009 Oct 12;10(10):2857-65. doi: 10.1021/bm9006826.

PMID:
19817491
19.

Characterization of chitosan acetate as a binder for sustained release tablets.

Nunthanid J, Laungtana-Anan M, Sriamornsak P, Limmatvapirat S, Puttipipatkhachorn S, Lim LY, Khor E.

J Control Release. 2004 Sep 14;99(1):15-26.

PMID:
15342177
20.

Supplemental Content

Support Center